ARQT

Arcutis Biotherapeutics Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↑ 8/10
  • Value↓ 0/10
Arcutis Biotherapeutics sales and earnings growth
ARQT Growth
Good
  • Revenue Y/Y↑ 91.34%
  • EPS Y/Y↑ 88.79%
  • FCF Y/Y↑ 94.38%
Arcutis Biotherapeutics gross and profit margin trends
ARQT Profitability
Neutral
  • Gross margin ↑ 90.20%
  • EPS margin↓ -4.30%
  • ROIC 5Y↓ -38.27%
Arcutis Biotherapeutics net debt vs free cash flow
ARQT Risk
Great
  • Debt / Equity↓ 0.6
  • Debt / FCF↑ 11.3
  • Interest coverage↓ -0.2

Arcutis Biotherapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗